Abstract Details
|
Jeffrey M. Kornitzer, MD
(New Jersey Pediatric Neuroscience Institute (NJPNI))
PRESENTER |
Dr. Kornitzer has nothing to disclose. |
| Aravindhan Veerapandiyan, MD (Arkansas Childrens Hospital/UAMS) | Dr. Veerapandiyan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AMO Pharma, AveXis, Biogen, Edgewise Therapeutics, FibroGen, Novartis, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Inc., UCB Pharma, Catalyst, Entrada, Scholar Rock, Catalyst, Lupin. Dr. Veerapandiyan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. The institution of Dr. Veerapandiyan has received research support from AMO Pharma, Capricor Therapeutics, Edgewise Therapeutics, FibroGen, Muscular Dystrophy Association, Novartis, Parent Project Muscular Dystrophy, Pfizer, RegenxBio and Sarepta Therapeutics. Dr. Veerapandiyan has received personal compensation in the range of $5,000-$9,999 for serving as a MD with PPMD, MDA. |
| Laurel Jakubowski, MD (SCVHHS) | No disclosure on file |
| Caroline Hayes-Rosen, MD (Rutgers - New Jersey Medical School) | No disclosure on file |
| Xue Ming, MD (Dept of Neurosciences) | Dr. Ming has nothing to disclose. |